AWHL on OTC
Aspira Women's Health Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Anbio Biotechnology, BIOMERICA INC or Insight Molecular Diagnostics Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
64.2%Gross margin3
-85.9%Operating margin3
-138.7%Net margin3
0.4%Revenue growth, 20253
-$7.0MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue36¢$3.3M
- Research and development31¢$2.9M
- Other costs33¢$3.0M
Out of $9.2M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $9.2M | $9.2M |
| Total cost of revenue | $3.3M | $3.7M |
| Gross profit | $5.9M | $5.5M |
| Research and development | $2.9M | $3.3M |
| Sales and marketing | $3.0M | $8.1M |
| General and administrative | $8.0M | $10.3M |
| Total operating expenses | $13.8M | $21.8M |
| Loss from operations | -$7.9M | -$16.3M |
| Change in fair value of warrant liabilities | -$5.6M | $1.3M |
| Change in fair value of convertible notes | $170.0K | |
| Loss upon issuance of convertible notes carried at fair value | -$1.2M | |
| Interest expense, net | -$41.0K | -$33.0K |
| Other income (expense), net | $1.8M | $1.9M |
| Total other (expense) income, net | -$4.9M | $3.2M |
| Net loss | -$12.8M | -$13.1M |
| Net loss per share - basic (in dollars per share) | -$0.37 | -$0.93 |
| Net loss per share - diluted (in dollars per share) | -$0.37 | -$0.93 |
| Weighted average common shares used to compute basic net loss per common share (in shares) | 34.1M shares | 14.1M shares |
| Weighted average common shares used to compute diluted net loss per common share (in shares) | 34.1M shares | 14.1M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash and cash equivalents | $1.8M | $1.8M |
| Accounts receivable, net of reserves of $44 | $1.2M | $990.0K |
| Prepaid expenses and other current assets | $845.0K | $1.1M |
| Inventories | $256.0K | $326.0K |
| Total current assets | $4.1M | $4.2M |
| Property and equipment, net | $47.0K | $69.0K |
| Intangible assets, net | $310.0K | |
| Right-of-use assets | $980.0K | $1.2M |
| Other assets | $56.0K | $45.0K |
| Total assets | $5.5M | $5.5M |
| Accounts payable | $1.2M | $2.2M |
| Accrued liabilities | $1.3M | $2.4M |
| Current portion of long-term debt | $236.0K | $229.0K |
| Short-term debt | $493.0K | $614.0K |
| Current maturities of lease liabilities | $202.0K | $7.0K |
| Total current liabilities | $3.5M | $5.5M |
| Long-term debt | $1.0M | $1.3M |
| Non-current maturities of lease liabilities | $1.0M | $1.2M |
| Warrant liabilities | $6.9M | $60.0K |
| Total liabilities | $12.4M | $8.1M |
| Common stock, par value $0.001 per share, 200,000,000 shares authorized at December 31, 2025 and December 31, 2024; 43,480,411 and 17,407,120 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $43.0K | $17.0K |
| Additional paid-in capital | $537.2M | $528.8M |
| Accumulated deficit | -$544.2M | -$531.4M |
| Total stockholders' deficit | -$6.9M | -$2.6M |
| Total liabilities and stockholders' deficit | $5.5M | $5.5M |
| Accounts receivable, allowance | $44.0K | $44.0K |
| Preferred stock, par value | $0.00 | $0.00 |
| Preferred stock, shares authorized | 5.0M shares | 5.0M shares |
| Preferred Stock, shares issued | 0 shares | 0 shares |
| Preferred Stock, shares outstanding | 0 shares | 0 shares |
| Common stock, par value | $0.00 | $0.00 |
| Common stock, shares authorized | 200.0M shares | 200.0M shares |
| Common stock, shares issued | 43.5M shares | 17.4M shares |
| Common stock, shares outstanding | 43.5M shares | 17.4M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Income (Loss) | -$12.8M | -$13.1M |
| Non-cash lease expense | $169.0K | $3.0K |
| Depreciation and amortization | $112.0K | $92.0K |
| Stock-based compensation expense | $531.0K | $1.5M |
| Change in fair value of warrant liabilities | $5.6M | -$1.3M |
| Change in fair value of March 2025 Convertible Notes | -$170.0K | |
| Loss upon issuance of March 2025 Convertible Notes carried at fair value | $1.2M | |
| Loss on impairment and disposal of property and equipment | $1.0K | $41.0K |
| Financing expense for entering into 2025 Lincoln Park Equity Line of Credit | $412.0K | |
| Accounts receivable | -$217.0K | $469.0K |
| Prepaid expenses and other assets | $242.0K | -$115.0K |
| Inventories | $68.0K | -$99.0K |
| Accounts payable | -$936.0K | $912.0K |
| Accrued liabilities | -$1.1M | -$418.0K |
| Other liabilities | -$118.0K | -$52.0K |
| Net cash used in operating activities | -$7.0M | -$12.1M |
| Purchase of property and equipment | -$16.0K | -$37.0K |
| Purchase of intangible assets | -$385.0K | |
| Net cash used in investing activities | -$401.0K | -$37.0K |
| Principal repayment of DECD loan | -$233.0K | -$93.0K |
| Proceeds from issuance of common stock from exercise of warrants | $112.0K | |
| Proceeds from March 2025 Convertible Notes | $1.4M | |
| Net cash provided by financing activities | $7.4M | $11.1M |
| Net decrease in cash and cash equivalents | -$14.0K | -$1.1M |
| Cash paid for interest | $34.0K | $49.0K |
| Increase in right-of-use assets | $895.0K | |
| Fair value of warrants issued in conjunction with Warrant Inducement Agreement | $1.3M | |
| Fair value of warrants issued upon conversion of Convertible Notes | $1.5M | |
| Fair value of common stock issued upon conversion of Convertible Notes | $916.0K |
Former names
Recent filings
- Oct 2, 20264
- Aug 14, 202610-Q
- Jul 17, 20264/A
- Jul 15, 20263
- Jul 15, 20268-K
- Jul 15, 20264
- Jul 7, 20268-K/A
- Jun 22, 20268-K
- Jun 22, 2026D
- Jun 17, 20268-K
- Jun 11, 2026SCHEDULE 13D/A
- Jun 9, 20268-K
- Jun 9, 20264
- May 29, 20264/A
- May 29, 20264/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10